BioSpace News Archive

Clinical Enterprise, Inc., a Eurofins Scientific Company, today announced it has launched a new partnership with Ginkgo Bioworks (NYSE: DNA) to support Operation Expanded Testing Program with the U.S. Department of Health and Human Services and Department of Defense.

Aptinyx Inc. today announced that Andy Kidd, M.D., president & chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference.

Galecto initiates Part 2 of Phase 1b/2a trial in patients with liver cirrhosis.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectins, provided an update on its strategy and clinical trial progress at its 2021 Annual Meeting, held virtually on December 3, and reported that shareholders approved all proposals, including the reelection of its Board of Directors.

Aprea Therapeutics, Inc. today announced updated results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML at the 2021 ASH Annual Meeting.

Oncternal Therapeutics, Inc. today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, that will be presented in a poster presentation at the American Society of Hematology (ASH) 2021 Annual Meeting.

BioTE Holdings, LLC today announced that they have entered into a definitive business combination agreement.

Equillium, Inc. today announced two poster presentations at the 63rd Annual Meeting of the American Society of Hematology.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually from January 5-7, 2022.

Increase in the prevalence of uterine fibroids in women is anticipated to bolster the growth of the global laparoscopic power morcellators market in coming years.